OKYO Pharma Ltd.
(NASDAQ : OKYO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.46%189.570.0%$920.63m
AMGNAmgen, Inc. 0.15%246.621.5%$592.91m
NVAXNovavax, Inc. 3.52%62.3975.7%$478.06m
VRTXVertex Pharmaceuticals, Inc. 1.08%291.131.9%$424.39m
GILDGilead Sciences, Inc. 0.49%61.391.0%$374.11m
REGNRegeneron Pharmaceuticals, Inc. 2.71%630.212.6%$353.77m
SNSSSunesis Pharmaceuticals, Inc. 0.78%3.900.7%$272.62m
ILMNIllumina, Inc. 2.09%228.443.3%$246.57m
BIIBBiogen, Inc. 1.68%221.871.8%$204.61m
GOVXGeoVax Labs, Inc. -4.35%3.080.0%$153.44m
BNTXBioNTech SE -8.32%167.870.0%$140.55m
CRSPCRISPR Therapeutics AG 2.06%83.080.6%$135.51m
RYTMRhythm Pharmaceuticals, Inc. 17.18%23.720.0%$106.99m
MRTXMirati Therapeutics, Inc. 6.60%92.271.6%$99.69m
BMRNBioMarin Pharmaceutical, Inc. 0.76%96.554.2%$96.06m

Company Profile

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It targets to cure and prevent the following conditions: dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, and ocular pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.